Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer

被引：0
|
作者：
Schmoll, H.
Tabernero, J.
Nowacki, M.
Maroun, J.
Price, T.
Lim, R.
Van Cutsem, E.
de Braud, F.
Haller, D.
机构：
[1] Univ Halle Wittenberg, Halle, K1Y 4K7, Germany
[2] Vall Hebron Univ Hosp, Barcelona, Spain
[3] Maria Sklodowska Curie Mem Canc Ctr, Inst Oncol, Warsaw 117548, Poland
[4] Ottawa Reg Canc Ctr, B-3000 Ottawa, ON, Canada
[5] Queen Elizabeth Hosp, Adelaide, SA, Australia
[6] Natl Univ Singapore Hosp, Singapore, 19104, Singapore
[7] Univ Hosp Gasthuisberg, Louvain, Belgium
[8] Ist Europeo Oncol, Milan, Italy
[9] Univ Penn, Philadelphia, PA USA
来源：
EJC SUPPLEMENTS | 2005年 / 3卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
下载
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [31] Capecitabine/cisplatin vs. continuous infusion of 5-FU/cisplatin as first-line therapy in patients (pts) with advanced gastric cancer (AGC):: a randomised phase III trial
    Kang, Y.
    Kang, W.
    Shin, D.
    Chen, J.
    Xiong, J.
    Wang, J.
    Lichinitser, M.
    Philco, M.
    Suarez, T.
    Santamaria, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 259 - 259
  • [32] Efficacy and safety findings from a randomized phase III study of capecitabine (X) plus oxaliplatin (O) (XELOX) vs. infusional 5-FU/LV + O (FOLFOX-6) for metastatic colorectal cancer (MCRC)
    Ducreux, M.
    Bennouna, J.
    Hebbar, M.
    Ychou, M.
    Lledo, G.
    Conroy, T.
    Adenis, A.
    Faroux, R.
    Rebischung, C.
    Douillard, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
    Diaz-Rubio, E
    Burris, H
    Douillard, JY
    Coxon, FY
    Maughan, T
    Bertetto, O
    Schueller, J
    Husseini, F
    Marschner, N
    Scheithauer, W
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 303S - 303S
  • [34] Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
    Allegra, Carmen J.
    Yothers, Greg
    O'Connell, Michael J.
    Beart, Robert W.
    Wozniak, Timothy F.
    Pitot, Henry C.
    Shields, Anthony F.
    Landry, Jerome C.
    Ryan, David P.
    Arora, Amit
    Evans, Lisa S.
    Bahary, Nathan
    Soori, Gamini
    Eakle, Janice F.
    Robertson, John M.
    Moore, Dennis F., Jr.
    Mullane, Michael R.
    Marchello, Benjamin T.
    Ward, Patrick J.
    Sharif, Saima
    Roh, Mark S.
    Wolmark, Norman
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11):
  • [35] A prospective randomized phase III trial of adjuvant chemotherapy with 5-fluorouracil (5-FU) and leucovorin (LV) in patients with stage II colon cancer
    Schippinger, W.
    Samonigg, H.
    Greil, R.
    Tschmelitsch, J.
    Steger, G.
    Jakesz, R.
    Gnant, M.
    Hofbauer, F.
    Rabl, H.
    Thaler, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [36] Cost-effectiveness analysis of oxaliplatin/5-fu/lv in adjuvant treatment of stage III colon cancer in the UK and Germany
    Aballea, S
    Chancellor, J
    Raikou, M
    Drummond, M
    Diel, R
    Frick, M
    Rosenfeld, S
    Boler, A
    Jourdan, S
    Paulo, C
    Bridgewater, J
    VALUE IN HEALTH, 2005, 8 (06) : A21 - A21
  • [37] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    Schippinger, W
    Jagoditsch, M
    Sorré, C
    Gnant, M
    Steger, G
    Hausmaninger, H
    Mlineritsch, B
    Schaberl-Moser, R
    Mischinger, HJ
    Hofbauer, F
    Holzberger, P
    Mittlböck, M
    Jakesz, R
    BRITISH JOURNAL OF CANCER, 2005, 92 (09) : 1655 - 1662
  • [38] A prospective randomised trial to study the role of levamisole and interferon alfa in an adjuvant therapy with 5-FU for stage III colon cancer
    W Schippinger
    M Jagoditsch
    C Sorré
    M Gnant
    G Steger
    H Hausmaninger
    B Mlineritsch
    R Schaberl-Moser
    H J Mischinger
    F Hofbauer
    P Holzberger
    M Mittlböck
    R Jakesz
    British Journal of Cancer, 2005, 92 : 1655 - 1662
  • [39] CAPECITABINE plus OXALIPLATIN (XELOX) VS. 5-FU/LV + OXALIPLATIN (FOLFOX4) IN THE ADJUVANT TREATMENT OF PATIENTS WITH COLON CANCER (ACC): COMPARISON OF DIRECT MEDICAL AND SOCIETAL (INDIRECT) COSTS
    Winterhalder, R.
    Delmore, G.
    van Lier, M.
    Urspruch, A.
    Hieke, K.
    VALUE IN HEALTH, 2010, 13 (07) : A269 - A269
  • [40] Interim analysis of a phase II trial evaluating the safety and efficacy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer
    Danno, Katsuki
    Hata, Taishi
    Tamai, Koki
    Fujie, Yujiro
    Ide, Yoshihito
    Kim, Ho Min
    Ohnishi, Tadashi
    Morita, Shunji
    Yoshioka, Shinichi
    Kudo, Toshihiro
    Nishimura, Junichi
    Matsuda, Chu
    Akamatsu, Hiroki
    Mizushima, Tsunekazu
    Nezu, Riichiro
    Doki, Yuichiro
    Mori, Masaki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (04) : 777 - 785
12345